Editas Medicine (EDIT) Cash from Operations (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Cash from Operations of 30843000.0 for Q3 2025, up 41.35% year-over-year from 21820344.72 in Q3 2024, and up 38.57% quarter-over-quarter from 50212000.0 in Q2 2025.
Powered by 
Analysis
Editas Medicine (EDIT) Cash from Operations (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Cash from Operations for 11 consecutive years, with 30843000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Cash from Operations rose 41.35% year-over-year to 30843000.0; the TTM figure through Sep 2025 stood at 179616000.0 (up 1.18% YoY), while the FY2024 annual figure was 210284000.0, down 59.09% from the prior year.
- Cash from Operations grew to 30843000.0 in Q3 2025 per EDIT's latest filing, from 50212000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 22240000.0 in Q4 2023 and bottomed at 57062000.0 in Q2 2024.
- Historically, Cash from Operations has averaged 42761473.68 across 5 years, with a median of 42273000.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash from Operations jumped 47.39% — and 2024, when it sank 128.25%.
- Editas Medicine's Cash from Operations stood at 34582000.0 in 2021, then fell by 22.24% to 42273000.0 in 2022, then surged by 47.39% to 22240000.0 in 2023, then tumbled by 128.25% to 50762000.0 in 2024, then jumped by 39.24% to 30843000.0 in 2025.
- Business Quant data shows EDIT's Cash from Operations at 30843000.0 in Q3 2025, 50212000.0 in Q2 2025, and 47799000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Editas Medicine | 287.84 Mn | 141.19 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -30.84 Mn |
| Jun 30, 2025 | -50.21 Mn |
| Mar 31, 2025 | -47.80 Mn |
| Dec 31, 2024 | -50.76 Mn |
| Sep 30, 2024 | -52.59 Mn |
| Jun 30, 2024 | -57.06 Mn |
| Mar 31, 2024 | -49.87 Mn |
| Dec 31, 2023 | -22.24 Mn |
| Sep 30, 2023 | -35.46 Mn |
| Jun 30, 2023 | -38.71 Mn |
| Mar 31, 2023 | -35.77 Mn |
| Dec 31, 2022 | -42.27 Mn |
| Sep 30, 2022 | -48.00 Mn |
| Jun 30, 2022 | -37.85 Mn |
| Mar 31, 2022 | -49.23 Mn |
| Dec 31, 2021 | -34.58 Mn |
| Sep 30, 2021 | -40.79 Mn |
| Jun 30, 2021 | -38.96 Mn |
| Mar 31, 2021 | -49.48 Mn |
| Dec 31, 2020 | -40.10 Mn |